Drug Type Small molecule drug |
Synonyms Thromboxane A2 receptor antagonists and Thromboxane A2 synthase inhibitors(University of Liège) |
Target |
Mechanism TBXA2R antagonists(Thromboxane A2 receptor antagonists), TXA2 synthase inhibitors(Thromboxane A2 synthase inhibitors) |
Therapeutic Areas |
Active Indication |
Inactive Indication- |
Originator Organization |
Active Organization |
Inactive Organization |
Drug Highest PhasePreclinical |
First Approval Date- |
Regulation- |
Molecular FormulaC21H24N6O4S |
InChIKeyOWNSPSHZBFKRMH-UHFFFAOYSA-N |
CAS Registry284464-35-3 |
Indication | Highest Phase | Country/Location | Organization | Date |
---|---|---|---|---|
Cardiovascular Diseases | Phase 1 | BE | - | |
Lung Diseases | Phase 1 | BE | - | |
Asthma | Preclinical | BE | 18 Feb 2010 | |
Myocardial Infarction | Preclinical | BE | 18 Feb 2010 |